Tokyo, Japan

Seiichi Ishizuka




Average Co-Inventor Count = 5.4

ph-index = 4

Forward Citations = 40(Granted Patents)


Location History:

  • Hino, JP (1980 - 2007)
  • Tokyo, JP (2003 - 2015)

Company Filing History:


Years Active: 1980-2015

Loading Chart...
Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: **Innovative Contributions of Seiichi Ishizuka in Pharmaceutical Research**

Introduction

Seiichi Ishizuka is a notable inventor based in Tokyo, Japan. With a remarkable portfolio of 10 patents, his work primarily focuses on pharmaceutical innovations aimed at addressing serious medical conditions.

Latest Patents

Ishizuka's most recent patents include a compound represented by a specific formula that is effective for treating Paget's disease of bone and hypercalcemia. This compound features complex chemical structures where R represents various groups, including hydrogen atoms, alkyl groups, or alkoxy groups. The invention describes a method for developing a treating agent for Paget's disease through the inhibition of the expression of the general transcription factor of steroid hormone receptors.

Career Highlights

Throughout his career, Seiichi Ishizuka has made significant strides in the pharmaceutical field, demonstrating expertise in drug development and composition. He has notably worked for Teijin Limited and Teijin Pharma Limited, where he contributed to various innovative projects.

Collaborations

Ishizuka has collaborated with respected colleagues in his field, including Kazuya Takenouchi and Qingzhi Gao. Their collective efforts have resulted in a series of advancements in the treatment options available for bone-related diseases.

Conclusion

In conclusion, Seiichi Ishizuka's contributions to the field of pharmaceutical research are invaluable. His dedication to innovation has enabled significant advancements in the treatment of complex medical conditions, enhancing patient care and outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…